Amlo Biosciences
Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
23
11 to 50 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
158
organic / mo
Sign up free to see all 5 verified contacts at Amlo Biosciences
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- JG
Jennifer Goodman
Medical Science Liaison · Science
EmailPhone - DM
David MacDonald
Non Executive Director · General Business & Management
EmailPhone - CG
Catherine Graham
Project Manager · General Business & Management
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Amlo Biosciences
4 distinct titles indexed · top 4 shown.
- 1medical science liaison
- 1non executive director
- 1project manager
- 1sales manager
Sign up to unlock all 5 contacts at Amlo Biosciences
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Amlo Biosciences
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.